三阴性乳腺癌中HOXD3表达与临床病理特征及预后的关系

临床肿瘤学杂志

三阴性乳腺癌中HOXD3表达与临床病理特征及预后的关系

吕鑫鑫，李聪，任延律，张清媛，李志高，张悦，程绍强

150081 哈尔滨哈尔滨医科大学附属肿瘤医院肿瘤内科

收稿日期:2015-09-17 修回日期:2015-12-17 出版日期:2016-03-30 发布日期:2016-03-30

Expression of HOXD3 in triple-negative breast cancer and its relationship with clinical pathological factors and prognosis

LV Xinxin， LI Cong， REN Yanlv， ZHANG Qingyuan， LI Zhigao， ZHANG Yue， CHENG Shaoqiang.

Department of Medical Oncology， the Affiliated Tumor Hospital of Harbin Medical University， Harbin 150081， China

Received:2015-09-17 Revised:2015-12-17 Online:2016-03-30 Published:2016-03-30

摘要/Abstract

摘要： 目的检测HOXD3在三阴性乳腺癌（TNBC）中表达，分析其表达与临床病理特征和预后的关系。方法免疫组化染色SP法检测89例TNBC标本中HOXD3蛋白表达，分析HOXD3表达与临床病理特征及预后的关系；采用Kaplan-Meire法绘制生存曲线并行Log-rank检验；采用Cox风险比例模型分析影响TNBC的独立预后因素。结果TNBC中HOXD3阳性表达率为69.7%（62/89），HOXD3表达与组织学分级及诺丁汉指数密切相关。HOXD3阳性表达者的中位生存期及无病生存期均显著低于HOXD3阴性者，差异有统计学意义（P＜0.05）。Cox单因素及多因素分析显示HOXD3是TNBC预后不良的独立危险因素。结论 HOXD3可作为判断TNBC预后的重要指标。

Abstract: Objective To investigate the expression of HOXD3 in triple-negative breast cancer （TNBC） and its relationship with clinical pathological factors and prognosis. Methods The expression of HOXD3 was detected in 89 TNBC tissues by immunohistochemical staining and compared with the clinicopathological features and the prognosis. Results The positive expression rate of HOXD3 in TNBC was 69.7%（62/89）， and it was closely associated with histological grade and NPI. The medium disease-free survival and overall survival of patients with positive HOXD3 expression were lower than those of patients with negative HOXD3 expression. Univariate and multivariate analyses showed that HOXD3 was an independent unfavorable prognostic factor for patients with TNBC. Conclusion HOXD3 can be used as a potentially useful prognostic marker for TNBC.

吕鑫鑫，李聪，任延律，张清媛，李志高，张悦，程绍强. 三阴性乳腺癌中HOXD3表达与临床病理特征及预后的关系[J]. 临床肿瘤学杂志, 2016, 21(3): 223-.

LV Xinxin， LI Cong， REN Yanlv， ZHANG Qingyuan， LI Zhigao， ZHANG Yue， CHENG Shaoqiang. . Expression of HOXD3 in triple-negative breast cancer and its relationship with clinical pathological factors and prognosis[J]. Chinese Clinical Oncology, 2016, 21(3): 223-.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed